Australian biotechnology EnGeneIC signs landmark agreement with

SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) – Australian company EnGeneIC has announced a historic agreement with the big American biotech ImmunityBio, on a revolutionary approach to both a COVID-19 vaccine and a cancer treatment.

Initial results from an adult clinical trial indicate that the antibodies generated can neutralize COVID-19 and all of its variants, including Delta.

EnGeneIC’s patented EDV ™ (EnGeneIC Dream Vector) nanocell technology also effectively targets and kills cancer cells with minimal toxicity, while stimulating an anti-tumor immune response. Phase I and IIa trials in patients with advanced pancreatic cancer are underway, and the FDA recently approved another trial in the United States.

The executive chairman of ImmunityBio is billionaire businessman, doctor and scientist Patrick Soon-Shiong, who invented the drug Abraxane, which is used in the treatment of pancreatic cancer. Dr Soon-Shiong is the owner of the Los Angeles Times and has a keen interest in tech company Zoom.

“It was so exciting and refreshing to find a company and its founders, who like us believe in the power of the immune system to fight cancer and infectious diseases such as COVID,” said Dr Soon-Shiong. “Drs. MacDiarmid and Brahmbhatt have dedicated their careers to making this vision a reality and we are honored to partner with EnGeneIC to transform the way these deadly diseases are treated. A critical part of the platform is the ability to democratize this technology across the world and bring much needed 21st century care to the underdeveloped world.

As part of the agreement, EnGeneIC will grant ImmunityBio an exclusive worldwide license to develop, manufacture and market EDV ™ in combination with its anti-cancer drugs and COVID-19 vaccine.

Co-CEOs Dr Himanshu Brahmbhatt and Dr Jennifer MacDiarmid described it as a “meeting of minds”. “We believe this collaboration will result in an effective vaccine, especially against mutants of concern, deployed in developing countries where vaccine deployment is a logistical challenge,” said Dr Brahmbhatt. EDVs can be stored and transported at room temperature and have a shelf life of one year.

EnGeneIC will also receive upfront payments and fees for future cancer control programs. “Stimulation of different types of immune cells for a broad anti-tumor immune response is essential to dramatically increase clinical response rates and overall survival,” said Dr. MacDiarmid.

ImmunityBio will build EDV ™ manufacturing facilities in the United States and South Africa, and cover costs associated with clinical trials and regulatory approvals.

The companies have agreed to a 50/50 share of net profit from worldwide sales of EDV ™ therapeutics.

For more information, images, animations and high resolution footage, please contact tracey@gemaker.com.au (0411) 281 854.

About EnGeneIC and EDV ™ Nanocell Technology
EnGeneIC is a clinical stage biopharmaceutical company developing its proprietary EDV ™ (EnGeneIC Dream Vector) nanocells for oncology and infectious disease applications. EDV is a powerful nanoparticle drug, siRNA or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the system’s innate and adaptive anti-tumor response. immune. EnGeneIC is currently in Phase IIa clinical trials in patients with incurable cancers, including patients with metastatic pancreatic cancer. www.engeneic.com

About ImmunityBio

ImmunityBio is one of the leading clinical advanced-stage immunotherapy companies developing next-generation therapies that stimulate immunogenic mechanisms to defeat cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cells and macrophages) and adaptive (T cells) immune systems to create long-term “immunological memory”. ImmunityBio has a comprehensive immunotherapy pipeline with more than 40 clinical trials (company sponsored or researcher initiated) – 25 of which are in phase II and III developmental stages – in 19 indications in solid cancers and fluids and infectious diseases. Currently, 17 first human immunotherapy agents are in clinical trials and, to date, more than 1,800 patients have been studied with our cytokine antibody fusion proteins, our albumin chemotherapy immunomodulators, our vaccines. Adeno and yeast and our natural commercial killer cell. some products. www.immunitybio.com


Source link

Comments are closed.